Sylvester Comprehensive Cancer Center, University of Miami | Strategic Alliance Partners

April 01, 2020

Richa Dawar, MD, discusses challenges with the use of neratinib in patients with metastatic HER2-positive breast cancer.

March 25, 2020

Atif Hussein, MD, and A. Craig Lockhart, MD, MHS, discuss the role of targeted therapy in colorectal and pancreatic cancer, the utility of regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) alone and in combination, and the importance of conducting next-generation sequencing.

March 17, 2020

Jonathan C. Trent, MD, PhD, discusses recent advances and ongoing research in the field of soft tissue sarcoma.

March 12, 2020

Elisa Krill-Jackson, MD, discusses the potential future utility of fam-trastuzumab deruxtecan-nxki in the treatment of patients with metastatic breast cancer.

February 18, 2020

A. Craig Lockhart, MD, MHS, professor and associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses dual-immunotherapy strategies in colorectal cancer (CRC).

January 17, 2020

Matthew P. Schlumbrecht, MD, discusses the treatment of women with uterine leiomyosarcoma.

January 16, 2020

Matthew P. Schlumbrecht, MD, discusses remaining challenges in uterine leiomyosarcoma.

January 14, 2020

A. Craig Lockhart, MD, MHS, professor and associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses investigational strategies targeting the RAS/RAF/MEK/ERK pathway in colorectal cancer (CRC).

January 13, 2020

Matthew P. Schlumbrecht, MD, discusses the role of surgical resection in uterine leiomyosarcoma.

January 10, 2020

A. Craig Lockhart, MD, MHS, discusses ongoing developments and the future of immunotherapy in colorectal cancer.

January 09, 2020

Matthew P. Schlumbrecht, MD, discusses ongoing challenges in diagnosing uterine leiomyosarcoma.

January 07, 2020

A. Craig Lockhart, MD, MHS, discusses the current treatment landscape of pancreatic cancer and how the introduction of olaparib in the frontline maintenance setting may benefit patients.

January 04, 2020

A. Craig Lockhart, MD, MHS, professor, associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses next steps for regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) in metastatic colorectal cancer (mCRC).

December 02, 2019

The director of Sylvester Comprehensive Cancer Center is named the first holder of the Oscar de la Renta Endowed Chair in Cancer Research.

July 30, 2019

Sylvester Comprehensive Cancer Center, part of the University of Miami Leonard M. Miller School of Medicine, has received the prestigious NCI designation from the National Cancer Institute.

June 26, 2019

Anlotinib, a novel tyrosine kinase inhibitor capable of mounting a multipronged attack against oncogenic processes, is being tested in rare soft tissue sarcoma subtypes where patients have limited therapeutic options.

May 09, 2019

Matthew P. Schlumbrecht, MD, associate professor and co-director of Cancer Prevention and Control, Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses investigational treatment strategies in uterine leiomyosarcoma.

April 12, 2019

James E. Hoffman, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses remaining challenges in the field of relapsed/refractory myeloma.

April 12, 2019

Craig Moskowitz, MD, physician-in-chief, Oncology Service Line, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of PET-adapted therapy in the treatment of patients with advanced-stage Hodgkin lymphoma.

April 08, 2019

Juan P. Alderuccio, MD, discusses the current state of the treatment paradigm in multiple myeloma and ongoing challenges that remain.